CONVINCE trial reveals the effect of long-term colchicine on recurrent stroke and cardiovascular events

FHS
May 16, 2024
5:39 pm

In the international CONVINCE trial, presented today (15 May 2024) at the European Stroke Organisation Conference (ESOC) 2024, anti-inflammatory treatment with long-term colchicine did not reduce rates of recurrent stroke and cardiovascular events in patients with non-cardioembolic stroke in the primary intention-to-treat analysis.

Major Source of Lupus Morbidity More Common in Certain Racial-Ethnic Groups

Among patients with systemic lupus erythematosus (SLE), high titers of anti-phospholipid (aPL) antibodies were most prevalent in whites and Latinos and less so for Black

October 26, 2023

Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline | Psychedelic Invest

–Company to host conference call to discuss positive Phase 2 CYB003 interim results today, November 1, 2023 at 11:00 a.m. ET – – Complete Phase

November 2, 2023

Communities at Center of Measles Outbreak Choose Medical Freedom Over Vax Mandates

SEMINOLE, Texas — Measles had struck this West Texas town, sickening dozens of children, but at the Community Church of Seminole, more than 350 worshippers

March 5, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.